Atrial Fibrillation Also called: AF, Afib

Clinical Trial Finder

Many patients with atrial fibrillation are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Atrial Fibrillation Registry in Jordan

Condition:   Atrial Fibrillation
Intervention:   Other: Observing medications prescribed per physicians discretion
Sponsor:   Jordan Collaborating Cardiology Group
Not yet recruiting - verified February 2016

Spironolactone in Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Drug: Spironolactone;   Drug: Placebo
Sponsor:   University of Birmingham
Recruiting - verified February 2016

Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock

Conditions:   New Onset Atrial Fibrillation;   Severe Sepsis;   Septic Shock
Intervention:   Drug: Amiodarone
Sponsor:   The University of Texas Health Science Center at San Antonio
Not yet recruiting - verified January 2016

Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery

Conditions:   Mild Tricuspid Regurgitation;   Moderate Tricuspid Regurgitation;   Tricuspid Regurgitation
Interventions:   Procedure: TV Annuloplasty;   Procedure: MVS Alone
Sponsors:   Icahn School of Medicine at Mount Sinai;   National Heart, Lung, and Blood Institute (NHLBI);   Canadian Institutes of Health Research (CIHR);   German Society for Thoracic and Cardiovascular Surgery
Not yet recruiting - verified February 2016

Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage

Condition:   Aortic Valve Disorder
Interventions:   Device: Lotus Heart valve system;   Device: WATCHMAN
Sponsor:   University Hospital Inselspital, Berne
Not yet recruiting - verified February 2016

Evaluation of Hospital Readmissions Among Hospitalized Non-valvular Atrial Fibrillation (NVAF) Patients in the US

Condition:   Nonvalvular Atrial Fibrillation
Intervention:  
Sponsor:   Bristol-Myers Squibb
Completed - verified February 2016

The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis

Condition:   Aortic Stenosis
Interventions:   Procedure: Surgical aortic valve replacement (SAVR);   Device: Transcatheter Aortic Valve Replacement (TAVR)
Sponsor:   Edwards Lifesciences
Not yet recruiting - verified February 2016

APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

Condition:   Anticoagulation
Interventions:   Drug: VKA;   Drug: Apixaban;   Drug: dabigatran;   Drug: rivaroxaban
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified January 2016

Exercise Training in Patients With Atrial Fibrillation (OPPORTUNITY Study)

Condition:   Atrial Fibrillation
Interventions:   Behavioral: moderate-intensity continuous exercise training;   Behavioral: high-intensity interval training
Sponsor:   Ottawa Heart Institute Research Corporation
Recruiting - verified November 2015

Patient Convenience Study

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Burden of Illness in Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Drug: Standard of care in AF in Denmark
Sponsor:   Bayer
Completed - verified February 2016

A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark

Condition:   Anticoagulation
Intervention:  
Sponsors:   Bristol-Myers Squibb;   University Hospital, Gentofte, Copenhagen
Recruiting - verified February 2016

Laser Ablation Study for trEatment of atRial Fibrillation (LASER)

Condition:   Atrial Fibrillation
Interventions:   Device: Laser ablation;   Device: RF ablation
Sponsors:   Hospital Clinic of Barcelona;   CardioFocus
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified February 2016

Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: ACP-196;   Drug: ibrutinib
Sponsor:   Acerta Pharma BV
Recruiting - verified February 2016

An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres

Conditions:   Stroke;   Prevention and Control;   Atril Fibrillation
Intervention:   Drug: Direct oral anticoagulants
Sponsor:   Bayer
Active, not recruiting - verified February 2016

Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)

Condition:   Anticoagulation, Blood Thinners , Atrial Fibrillation, Bleeding, Stroke
Intervention:  
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified February 2016

Atrial Fibrillation General Registry

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   European Society of Cardiology
Recruiting - verified February 2016

Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified February 2016

Left Atrial Geometry and Outcomes After Atrial Fibrillation Ablation

Conditions:   Atrial Fibrillation;   Recurrence
Intervention:  
Sponsors:   Hospital Clinic of Barcelona;   Germans Trias i Pujol Hospital;   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau;   Hospital del Mar;   Hospital Virgen de la Salud;   Hospital San Carlos, Madrid;   Fundación para la Investigación del Hospital Clínico de Valencia;   Complexo Hospitalario Universitario de Vigo;   Puerta de Hierro University Hospital
Active, not recruiting - verified November 2015

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Condition:   Atrial Fibrillation
Interventions:   Drug: Warfarin;   Drug: Dabigatran Etexilate 150mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Measurement of Low-energy Stimulation in Patients With Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Device: Multistage low-energy stimulation
Sponsor:   Cardialen, Inc.
Recruiting - verified February 2016

Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department

Condition:   Atrial Fibrillation
Interventions:   Drug: Pharmacological cardioversion;   Procedure: Electrical cardioversion;   Drug: Metoprolol;   Drug: Verapamil;   Drug: Digoxin
Sponsors:   Maastricht University Medical Center;   ZonMw: The Netherlands Organisation for Health Research and Development
Recruiting - verified September 2015

Off Pump Versus On Pump Coronary Artery Bypass Grafting in Frailty Patients (FRAGILE)

Conditions:   Coronary Artery Disease;   Complications Due to Coronary Artery Bypass Graft;   Fragility
Interventions:   Procedure: OPCAB;   Procedure: CABG
Sponsors:   University of Sao Paulo General Hospital;   InCor Heart Institute;   Cardiac Emergency Hospital of Pernambuco;   Alberto Urquiza Wanderley Hospital of João Pessoa;   Pitangueiras Hospital of Jundiaí;   University of Campinas, Brazil;   Cardiology Institute of the Distrito Federal;   National Cardiology Institute;   Federal University of São Paulo;   Pontifícia Universidade Católica do Paraná;   Clinical Hospital Samuel Libânio of Pouso Alegre;   Beneficência Portuguesa of São Paulo;   Pontifical University Catholic of Campinas;   InCor Heart Institute of Natal
Not yet recruiting - verified January 2016

Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke

Conditions:   Stroke;   Atrial Fibrillation
Interventions:   Other: prolonged ECG monitoring;   Device: ECG
Sponsors:   Charite University, Berlin, Germany;   Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Recruiting - verified February 2016

Safety and Performance of a GLOBAL Mapping and Ablation Device for the Treatment of Atrial Fibrillation (GLOBAL-AF)

Condition:   Atrial Fibrillation
Intervention:   Device: Global mapping and ablation device
Sponsor:   Kardium Inc.
Recruiting - verified February 2016

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers

Condition:   Atrial Fibrillation
Interventions:   Drug: BMS-919373;   Drug: Sotalol;   Drug: Placebo for BMS-919373
Sponsor:   Bristol-Myers Squibb
Recruiting - verified August 2015

Ambulatory Electrocardiographic Monitoring for the Detection of High-Degree Atrio-Ventricular Block in Patients With New-onset PeRsistent LEft Bundle Branch Block After Transcatheter Aortic Valve Implantation. The "MARE" Study

Conditions:   Aortic Valve Disease;   Conduction Disturbances
Intervention:   Device: Implantable loop recorders system Reveal ICM LINQ®,
Sponsor:   Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Recruiting - verified February 2016

HEart and BRain Interfaces in Acute Ischemic Stroke

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsors:   Charite University, Berlin, Germany;   Center for Stroke Research Berlin
Recruiting - verified January 2016

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Condition:   Paroxysmal Atrial Fibrillation
Interventions:   Drug: BMS-919373;   Drug: Placebo (Matching with BMS-919373)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2016

Measurement of NonInvasive Blood Pressure in Neonates Through Adults and Special Populations

Condition:   Blood Pressure
Intervention:   Procedure: Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM)
Sponsor:   GE Healthcare
Enrolling by invitation - verified February 2016

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

SORT - AF Supervised Obesity Reduction Trial for AF Ablation Patients

Conditions:   Atrial Fibrillation;   Obesity;   Sleep Apnea
Interventions:   Procedure: Intervention group;   Procedure: control group
Sponsors:   Universitätsklinikum Hamburg-Eppendorf;   St. Jude Medical
Recruiting - verified February 2016

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Condition:   Atrial Fibrillation
Intervention:   Drug: Observational
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified February 2016

Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control

Conditions:   Atrial Fibrillation;   Atrial Flutter
Interventions:   Drug: Metoprolol;   Drug: Diltiazem
Sponsor:   CAMC Health System
Recruiting - verified January 2016

Evaluation of Goal-Directed Intraoperative Hemodynamic Optimization Protocol

Condition:   Postoperative Complications
Intervention:  
Sponsor:   University of California, Irvine
Recruiting - verified February 2016

Essential Hypotension and Adaptability Registry

Conditions:   Blood Pressure;   Depression;   Panic Attack;   Fibromyalgia;   POTS;   Inappropriate Sinus Tachycardia;   Coronary Heart Disease;   Acute Coronary Syndrome (ACS);   Acute Myocardial Infarction (AMI);   Cerebrovascular Disease (CVD);   Transient Ischemic Attack (TIA);   Atrial Fibrillation;   Diabetes Mellitus;   Cancer;   Systolic Heart Failure;   Diastolic Heart Failure;   Chronic Fatigue Syndrome;   Syncope;   Vasovagal Syncope
Intervention:  
Sponsor:   CES University
Recruiting - verified February 2016

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

Condition:   Current or Recent History of Atrial Fibrillation
Interventions:   Drug: bucindolol hydrochloride;   Drug: metoprolol succinate
Sponsors:   ARCA Biopharma, Inc.;   Medtronic
Recruiting - verified February 2016

Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Conditions:   Rivaroxaban;   Cancer-associated Thrombosis;   Recurrence;   Bleeding
Intervention:   Drug: Rivaroxaban
Sponsors:   Seoul National University Hospital;   Korean Society of Hematology Thrombosis Working Party
Recruiting - verified February 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Stroke
Interventions:   Drug: Apixaban;   Drug: aspirin
Sponsors:   Population Health Research Institute;   Bristol-Myers Squibb;   Pfizer;   Medtronic
Recruiting - verified February 2016

Anticoagulant Utilization Pattern

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea

Condition:   Atrial Fibrillation
Intervention:   Drug: Pradaxa (Dabigatran etexilate mesilate)
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia

Condition:   Atrial Fibrillation
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Recruiting - verified February 2016

Safety and Efficacy of Cryothermia to Treat Longstanding Persistent Atrial Fibrillation (AF)

Condition:   Longstanding Persistent Atrial Fibrillation
Intervention:   Device: Medtronic Cardioblate CryoFlex
Sponsor:   Medtronic Bakken Research Center
Active, not recruiting - verified February 2016

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Remote Ischemic Conditioning and Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG)

Condition:   Atrial Fibrillation
Interventions:   Procedure: Remote ischemic conditioning;   Procedure: Sham
Sponsor:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Terminated - verified February 2016

Implantable Loop Recorders in Post-atrial Fibrillation (AF) Ablation: RPAF-A

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   The Cleveland Clinic
Completed - verified January 2016

Safety and Effectiveness of Oral Alendronate Therapy on Bone Mineral Density in HIV-infected Children and Adolescents With Low Bone Mineral Density

Condition:   HIV Infections
Interventions:   Drug: Alendronate;   Drug: Alendronate placebo;   Dietary Supplement: Calcium carbonate/vitamin D
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting - verified February 2016

Surgical or Catheter Ablation of Lone Atrial Fibrillation (AF) Patients

Condition:   Atrial Fibrillation
Interventions:   Procedure: Catheter Ablation;   Procedure: Surgical Ablation
Sponsor:   Medtronic Bakken Research Center
Active, not recruiting - verified January 2016

Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF

Condition:   Atrial Fibrillation
Intervention:   Other: Aggressive Blood Pressure control
Sponsors:   Nova Scotia Health Authority;   Nova Scotia Health Research Foundation
Active, not recruiting - verified January 2016

Lifetime Risk for Cardiovascular Disease Among Non-White Ethnic Groups

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Heart Failure, Congestive;   Atrial Fibrillation
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified December 2007

Epidemiology of Symptomatic Arrhythmias

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Atrial Fibrillation;   Arrhythmia;   Tachycardia;   Tachycardia, Supraventricular
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified May 2000

CardioSmart Points

Log in to Check Your Balance
and Go Shopping

Learn how to earn more CardioSmart Points